

Supporting Information for

**Tartrate-derived iminophosphorane catalyzed asymmetric
hydroxymethylation of 3-substituted oxindoles with
paraformaldehyde**

Xing Gao,^{a,b} Jianwei Han^{*b} and Limin Wang^{*a}

-
- a* Department Key Laboratory for Advanced Materials and Institute of Fine Chemicals, East China University of Science and Technology, Meilong Road, 130, Shanghai 200237, P. R. China. Tel/Fax: (+)-86-21-64253881.
E-mail: wanglimin@ecust.edu.cn
- b* Shanghai-Hong Kong Joint Laboratory in Chemical Synthesis, Shanghai Institute of Organic Chemistry, The Chinese Academy of Sciences, Ling Ling Road, 345, Shanghai 200237, P. R. China. Fax: (+)-86-21-54925383.
E-mail: jianwei.han@sioac.ac.cn

Contents

1. General information.	2
2. Experimental Section.	2
3. General procedure for hydroxymethylation of 3-substituted oxindoles with paraformaldehyde.	6
4. References.	14
5. HPLC Spectra for 3 (a-s).	16
6. NMR Spectra for 3(a-s), 7(a, b), 8(a, b), 9(a, b) and 4(f, i).	35


1. General information.

Unless otherwise noted, materials were purchased from commercial suppliers and used without further purification. All the solvents were treated according to general methods. Paraformaldehyde was used as obtained from commercial sources (CAS 30525-89-4, Sinopharm Chemical Reagent Co., Ltd, $\geq 94.0\%$). 1,3,5-Trimethylbenzene was from Shanghai Tianlian Chemical Technology Co., Ltd. (CAS 108-67-8). Flash column chromatography was performed with SiliaFlash®P60 (230–400 mesh, UltraPure SILICA GELS, SiliCycle). ^1H NMR, ^{13}C NMR, ^{19}F NMR and ^{31}P NMR spectra were recorded on a Mercury 300 NMR spectrometer, and TMS was used as a reference. ^1H NMR spectroscopic data are represented as follows: chemical shift (ppm), multiplicity (s = singlet, d = doublet, t = triplet, dd = doublet of doublets, m = multiplet), coupling constants in hertz (Hz), integration, assignment. ^{13}C NMR, ^{19}F NMR and ^{31}P NMR spectroscopic data are reported in ppm. IR spectra were recorded on a Nicolet iN10 MX spectrometer and are reported in wavenumbers (cm^{-1}). High-resolution mass spectra were measured on a Agilent Technologies 6224 TOF LC/MS spectrometer. Enantiomeric excess was measured by HPLC with CHIRALCEL OD-H on a DIONEX UltiMate 3000, ThermoScientific. Optical rotation was measured on an Autopol I, serial number 30575. All melting points were determined using a digital melting point apparatus and were uncorrected.

The starting oxindole derivatives were prepared according to literature procedures.¹ Compounds described in the literature were characterized by comparing their spectral data to the reported values.


2. Experimental Section.

Chiral iminophosphoranes **4f** and **4i** were prepared by following the published general procedure.²



(*R,R*)-Dimethyl O,O-cyclohexylidenetartrate **6b** was synthesized according to literature


procedures.³




To a solution of L-dimethyl tartrate (9.82 g, 55.1 mmol, 1.5 equiv.) in THF (150 mL) at -30 °C under inert atmosphere was added successively 1,1-dimethoxycyclohexane (5.3 g, 36.75 mmol, 1.0 equiv.) and BF₃·Et₂O (5.45 mL, 44.1 mmol, 1.2 equiv.) dropwise. The resulting mixture was then stirred for 3 h having the temperature raised from -30 °C to RT. The reaction was then cooled to 0 °C and carefully quenched with sat. aqueous NaHCO₃ solution. The organic layer was then separated and the aqueous phase was extracted with EtOAc (3 X 400 mL). The combined organic phases were washed with water (2 X 400 mL) and brine (1 X 400 mL). The combined organic extracts were dried over Na₂SO₄, filtered, and concentrated in vacuo to afford a crude oil, which was further purified by flash chromatography (gradient of EtOAc/hexanes 2:98 to 15:85) affording a colorless oil (8.07 g, 31.23 mmol, 85%).³ ¹H NMR (300 MHz, CDCl₃): δ = 4.76 (s, 2H), 3.76 (s, 6H), 1.69 – 1.50 (m, 8H), 1.42 – 1.28 (m, 2H). ¹³C NMR (75 MHz, CDCl₃): δ = 170.52, 114.82, 76.86, 52.93, 35.91, 24.97, 23.88.

Characterization Data:

Characterization data of TADDOL 7a and 7b:



7a, 84% yield, white solid. $[\alpha]_D^{25} = -57.5^\circ$ ($c = 0.50$, CHCl₃). ¹H NMR (300 MHz, CDCl₃): δ = 7.45 (d, $J = 8.1$ Hz, 4H), 7.28 (d, $J = 8.2$ Hz, 4H), 7.17 (d, $J = 8.0$ Hz, 4H), 7.11 (d, $J = 8.2$ Hz, 4H), 4.58 (s, 2H), 4.13 (s, 2H), 2.66 (dq, $J = 22.5, 7.5$ Hz, 8H), 1.28 (t, $J = 7.6$ Hz, 6H), 1.22 (t, $J = 7.6$ Hz, 6H), 1.07 (s, 6H). ¹³C NMR (75 MHz, CDCl₃): δ = 143.77, 143.50, 143.13, 140.29, 128.86, 127.93, 127.78, 126.94, 109.50, 81.27, 78.17, 28.75, 28.72, 27.44, 15.78, 15.68. IR (KBr): 3303, 3026, 2963, 2931, 2872, 1510, 1455, 1412, 1378, 1369, 1242, 1216, 1168, 1061, 1040, 1018, 887, 827, 756, 617 cm⁻¹. HRMS (ESI) Calcd. for C₃₉H₅₀NO₄⁺ ($[M+NH_4]^+$) 596.3734, found 596.3733.




7b, 88% yield, white solid. ¹H NMR (300 MHz, CDCl₃): δ = 7.55 – 7.48 (m, 4H), 7.41 – 7.22 (m, 16H), 4.55 (s, 2H), 3.98 (s, 2H), 1.50 – 1.33 (m, 4H), 1.30 – 1.09 (m, 6H). ¹³C NMR (75 MHz, CDCl₃): δ = 146.35, 142.90, 128.84, 128.34, 127.94, 127.76, 127.40, 110.16, 80.65, 78.48, 70.85, 36.74, 26.71, 25.28, 24.20. HRMS (ESI) Calcd. for C₃₄H₃₈NO₄⁺ ($[M+NH_4]^+$) 524.2795, found 524.2796. The spectral data are identical to those in reference 4.


Synthesis and characterization data of TADDOL-N₃ 8a and 8b:

Caution!: This reaction should be conducted behind a safety screen in a good hood because hydrazoic acid is very toxic. Care should also be taken in handling sodium azide (NaN₃).

A round-bottomed flask was charged with CHCl_3 (31 mL) and sodium azide (9.5 g, 146.4 mmol). The mixture was cooled with an ice-salt bath, then trifluoroacetic acid (TFA, 31 mL) was added to this stirring solution. After 5-10 min, 4-EtPhTADDOL **7a** (14.1 g, 24.4 mmol) dissolved in CHCl_3 was added slowly to the stirring mixture with the ice-salt bath. After that, the resulting slurry was stirred at 0 °C. Following, after the reaction was finished detected by TLC, the resulting mixture was poured into ice-water solution with stirring and cautiously neutralized with a slight excess of 12-15% aqueous ammonia solution, then transferred to a separating funnel. The chloroform layer was separated, and the aqueous solution was extracted with 100 mL of CH_2Cl_2 . The combined organic extracts were washed with 50 mL of water, separated, and dried over anhydrous Na_2SO_4 . After evaporation of the solvent, the crude residue was purified by column chromatography on silica gel to give TADDOL- N_3 **8a**.²




8a, 13.5 g, 21.5 mmol, 88% yield, white solid. $[\alpha]^{30}_{\text{D}} = -46.2^\circ$ ($c = 0.50$, CHCl_3). ^1H NMR (300 MHz, CDCl_3): $\delta = 7.27 - 7.11$ (m, 16H), 4.92 (s, 2H), 2.73 – 2.56 (m, 8H), 1.30 – 1.17 (m, 12H), 1.09 (s, 6H). ^{13}C NMR (75 MHz, CDCl_3): $\delta = 143.79$, 143.70, 139.51, 137.77, 129.83, 128.48, 127.70, 127.30, 110.75, 80.83, 73.34, 28.66, 27.73, 15.59, 15.46. IR (KBr): 3026, 2964, 2932, 2873, 2106, 1510, 1460, 1412, 1379, 1370, 1242, 1216, 1165, 1072, 977, 878, 826, 753, 685 cm^{-1} . HRMS (ESI) Calcd. for $\text{C}_{39}\text{H}_{44}\text{N}_6\text{O}_2\text{K}^+$ ($[\text{M}+\text{K}]^+$) 667.3157, found 667.3109.




8b, 10.7 g, 19.2 mmol, 81% yield, white solid. ^1H NMR (300 MHz, CDCl_3): $\delta = 7.41 - 7.25$ (m, 20H), 4.95 (s, 2H), 1.52 – 1.39 (m, 4H), 1.36 – 1.21 (m, 6H). ^{13}C NMR (75 MHz, CDCl_3): $\delta = 142.34$, 140.53, 129.86, 128.61, 128.41, 128.03, 127.90, 127.85, 111.08, 80.23, 73.41, 36.98, 25.23, 24.39. HRMS (ESI) Calcd. for $\text{C}_{34}\text{H}_{32}\text{N}_6\text{O}_2\text{Na}^+$ ($[\text{M}+\text{Na}]^+$) 579.2479, found 579.2461. The spectral data are identical to those in reference 4.

Characterization data of TADDOL- NH_2 **9a** and **9b**:




9a, 97% yield, white solid. $[\alpha]^{31}_{\text{D}} = -46.3^\circ$ ($c = 0.53$, CHCl_3). ^1H NMR (300 MHz, CDCl_3): $\delta = 7.49$ (d, $J = 7.9$ Hz, 4H), 7.20 (d, $J = 8.0$ Hz, 4H), 7.11 (q, $J = 8.3$ Hz, 8H), 4.29 (s, 2H), 2.74 (q, $J = 15.0$, 7.5 Hz, 4H), 2.63 (q, $J = 14.9$, 7.4 Hz, 4H), 2.33 (s, 4H), 1.33 (t, $J = 7.6$ Hz, 6H), 1.24 (t, $J = 7.6$ Hz, 6H), 1.17 (s, 6H). ^{13}C NMR (75 MHz, CDCl_3): $\delta = 147.72$, 142.79, 142.33, 141.44,

129.38, 127.68, 127.65, 126.92, 107.56, 82.17, 62.35, 28.70, 28.59, 27.49, 15.74, 15.66. IR (KBr): 3248, 3160, 3022, 2962, 2930, 2872, 1584, 1508, 1455, 1411, 1368, 1237, 1172, 1065, 1020, 894, 825, 761, 613 cm^{-1} . HRMS (ESI) Calcd. for $\text{C}_{39}\text{H}_{49}\text{N}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$) 577.3789, found 577.3788.




9b, 97% yield, white solid. ^1H NMR (300 MHz, CDCl_3): δ = 7.62 – 7.51 (m, 4H), 7.39 – 7.28 (m, 6H), 7.27 – 7.13 (m, 10H), 4.22 (s, 2H), 2.38 (s, 4H), 1.46 (d, J = 3.2 Hz, 4H), 1.30 (d, J = 5.8 Hz, 6H). ^{13}C NMR (75 MHz, CDCl_3): δ = 150.40, 144.10, 129.57, 128.22, 127.89, 127.48, 127.24, 127.18, 126.65, 108.03, 81.66, 63.01, 36.85, 25.49, 24.26. HRMS (ESI) Calcd. for $\text{C}_{34}\text{H}_{37}\text{N}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$) 505.2850, found 505.2851. The spectral data are identical to those in reference 4.

Characterization data of iminophosphoranes **4f** and **4i**:




4f, 90% yield, white solid. $[\alpha]_D^{32} = -88.2^\circ$ (c = 0.53, CHCl_3). ^1H NMR (300 MHz, CDCl_3): δ = 7.42 (s, 8H), 7.01 (s, 24H), 4.93 (s, 4H), 3.08 – 2.37 (m, 19H), 1.36 – 0.55 (m, 36H). ^{13}C NMR (100 MHz, CDCl_3): δ = 146.05, 142.24, 141.71, 129.89, 127.50, 127.14, 126.61, 109.59, 82.76, 77.32, 65.50, 28.42, 27.06, 15.62, 15.20. ^{31}P NMR (121 MHz, CDCl_3): δ = -6.04 (s). IR (KBr): 3363, 3022, 2963, 2931, 2872, 1508, 1456, 1411, 1378, 1240, 1216, 1164, 1061, 1018, 963, 907, 889, 823, 795, 753, 598 cm^{-1} . HRMS (MALDI/DHB): Calcd for $\text{C}_{78}\text{H}_{92}\text{N}_4\text{O}_4\text{P}^+$ ($[\text{M}+\text{H}]^+$) 1179.6851, found 1179.6856.




4i, 94% yield, white solid. $[\alpha]_D^{31} = -74.9^\circ$ (c = 0.59, CHCl_3). ^1H NMR (300 MHz, CDCl_3): δ = 7.70 – 6.49 (m, 40H), 4.92 (d, J = 61.6 Hz, 4H), 2.80 (s, 3H), 1.58 – 0.58 (m, 20H). ^{13}C NMR (100 MHz, CDCl_3): δ = 142.20, 138.23, 124.58, 122.72, 122.60, 122.19, 121.80, 121.35, 105.19, 75.83, 71.98, 61.27, 60.22, 31.20, 19.72, 18.60. ^{31}P NMR (121 MHz, CDCl_3): δ = -6.84 (s). IR (KBr): 3361, 3056, 3027, 2932, 2858, 1599, 1493, 1445, 1365, 1278, 1165, 1127, 1099, 1050, 953, 908, 893, 745, 698, 640 cm^{-1} . HRMS (MALDI/DHB): Calcd for $\text{C}_{62}\text{H}_{60}\text{N}_4\text{O}_4\text{P}^+$ ($[\text{M}+\text{H}]^+$) 1035.4973, found 1035.4973.

3. General procedure for hydroxymethylation of 3-substituted oxindoles with paraformaldehyde.




To a tube was added oxindole **1** (0.1 mmol, 1.0 equiv), **cat.** (7.0 mg, 0.005 mmol, 5 mol %) and mesitylene (2 mL) at 25 °C with magnetic stirring. Then paraformaldehyde **2** (9.0 mg, 0.3 mmol, 3.0 equiv) was added to the mixture of oxindole and catalyst. After stirring for 24 h at 25 °C, the reaction mixture was purified directly by silica gel column chromatography to yield product **3**. The *ee* of product **3** was determined by chiral HPLC analysis. The absolute configuration of compound **3** was determined to be “(S)” by comparison of the optical rotation value to the reported literature value.⁵

(S)-tert-butyl-3-benzyl-3-(hydroxymethyl)-2-oxoindoline-1-carboxylate (3a):⁵




White solid, 34.6 mg, 98% yield, 94% *ee*; m.p. 107 – 108 °C. $[\alpha]_{\text{D}}^{30} = +26.2^\circ$ ($c = 0.88$, CHCl_3). Enantiomeric excess was determined by chiral HPLC analysis (CHIRALCEL OD-H, 254 nm, 9:1 hexane/*i*PrOH, 1.0 mL /min): t_{R} (major) = 6.52 min, t_{R} (minor) = 7.38 min. ^1H NMR (300 MHz, CDCl_3): $\delta = 7.63$ (d, $J = 7.9$ Hz, 1H), 7.30 – 7.18 (m, 1H), 7.18 – 6.99 (m, 5H), 6.94 – 6.79 (m, 2H), 4.03 (d, $J = 10.9$ Hz, 1H), 3.87 (d, $J = 11.0$ Hz, 1H), 3.15 (q, $J = 13.1$ Hz, 2H), 2.82 (br s, 1H), 1.55 (s, 9H). ^{13}C NMR (75 MHz, CDCl_3): $\delta = 178.17$, 148.91, 140.30, 134.98, 130.19, 128.79, 128.27, 128.07, 127.02, 124.44, 123.88, 115.17, 84.49, 66.67, 56.50, 40.35, 28.25. HRMS (ESI): Calcd. for $\text{C}_{21}\text{H}_{23}\text{NO}_4\text{Na}$ ($[\text{M}+\text{Na}]^+$) 376.1519; found 376.1520.

(S)-tert-butyl-3-benzyl-3-(hydroxymethyl)-5-methyl-2-oxoindoline-1-carboxylate (3b):⁵



White solid, 35.2 mg, 96% yield, 93% *ee*; m.p. 82 – 83 °C. $[\alpha]_{\text{D}}^{30} = -16.6^\circ$ ($c = 0.91$, CHCl_3). Enantiomeric excess was determined by chiral HPLC analysis (CHIRALPAK AD-H, 254 nm, 9:1 hexane/*i*PrOH, 1.0 mL /min): t_{R} (major) = 7.72 min, t_{R} (minor) = 6.77 min. ^1H NMR (300 MHz, CDCl_3): $\delta = 7.50$ (d, $J = 8.3$ Hz, 1H), 7.16 – 6.98 (m, 4H), 6.95 – 6.80 (m, 3H), 4.02 (d, $J = 10.4$ Hz, 1H), 3.86 (d, $J = 11.1$ Hz, 1H), 3.14 (q, $J = 13.1$ Hz, 2H), 2.64 (br s, 1H), 2.33 (s, 3H), 1.55 (s, 9H). ^{13}C NMR (75 MHz, CDCl_3): $\delta = 178.37$, 148.94, 137.94, 135.03, 134.02, 130.23, 129.30, 128.09, 128.03, 127.01, 124.37, 114.97, 84.33, 66.63, 56.33, 40.31, 28.25, 21.37. HRMS (ESI): Calcd. for $\text{C}_{22}\text{H}_{25}\text{NO}_4\text{Na}$ ($[\text{M}+\text{Na}]^+$) 390.1676; found 390.1676.


(S)-tert-butyl-3-benzyl-3-(hydroxymethyl)-5-methoxy-2-oxoindoline-1-carboxylate (3c):



White solid, 35.2 mg, 92% yield, 93% ee; m.p. 100 – 101 °C. $[\alpha]^{30}_D = -$

20.0° ($c = 1.14$, CHCl_3). Enantiomeric excess was determined by chiral HPLC analysis (CHIRALPAK AD-H, 254 nm, 9:1 hexane/iPrOH, 1.0 mL /min): t_R (major) = 11.97 min, t_R (minor) = 10.28 min. ^1H NMR (300 MHz, CDCl_3): $\delta = 7.55$ (d, $J = 8.9$ Hz, 1H), 7.17 – 7.02 (m, 3H), 6.96 – 6.84 (m, 2H), 6.75 (dd, $J = 8.9, 2.6$ Hz, 1H), 6.61 (d, $J = 2.6$ Hz, 1H), 4.08 – 3.94 (m, 1H), 3.85 (d, $J = 11.0$ Hz, 1H), 3.74 (s, 3H), 3.23 – 3.04 (m, 2H), 2.71 (d, $J = 5.0$ Hz, 1H), 1.55 (s, 9H). ^{13}C NMR (75 MHz, CDCl_3): $\delta = 178.24, 156.76, 148.95, 134.94, 133.64, 130.29, 129.53, 128.10, 127.07, 116.09, 113.47, 110.17, 84.34, 66.55, 56.51, 55.81, 40.21, 28.25$. IR (KBr): 3495, 3030, 2979, 2932, 1782, 1728, 1600, 1487, 1455, 1436, 1394, 1369, 1337, 1281, 1248, 1152, 1074, 1036, 1000, 952, 843, 812, 769, 738, 700, 612, 582, 536 cm^{-1} . HRMS (ESI): Calcd. for $\text{C}_{22}\text{H}_{25}\text{NO}_5\text{Na}$ ($[\text{M}+\text{Na}]^+$) 406.1625; found 406.1627.


(S)-tert-butyl-3-(hydroxymethyl)-3-(4-methylbenzyl)-2-oxoindoline-1-carboxylate (3d):⁵



White solid, 33.0 mg, 90% yield, 93% ee; m.p. 83 – 84 °C. $[\alpha]^{30}_D = + 31.5^\circ$ ($c =$

0.93, CHCl_3). Enantiomeric excess was determined by chiral HPLC analysis (CHIRALPAK AS-H, 254 nm, 9:1 hexane/iPrOH, 1.0 mL /min): t_R (major) = 9.51 min, t_R (minor) = 7.78 min. ^1H NMR (300 MHz, CDCl_3): $\delta = 7.65$ (d, $J = 8.1$ Hz, 1H), 7.29 – 7.20 (m, 1H), 7.18 – 7.05 (m, 2H), 6.88 (d, $J = 7.8$ Hz, 2H), 6.76 (d, $J = 7.9$ Hz, 2H), 4.02 (d, $J = 10.7$ Hz, 1H), 3.86 (d, $J = 11.1$ Hz, 1H), 3.11 (q, $J = 13.2$ Hz, 2H), 2.71 (br s, 1H), 2.21 (s, 3H), 1.57 (s, 9H). ^{13}C NMR (75 MHz, CDCl_3): $\delta = 178.31, 148.96, 140.34, 136.50, 131.79, 130.10, 128.79, 128.76, 128.35, 124.41, 123.86, 115.20, 84.49, 66.64, 56.42, 39.89, 28.25, 21.24$. HRMS (ESI): Calcd. for $\text{C}_{22}\text{H}_{25}\text{NO}_4\text{Na}$ ($[\text{M}+\text{Na}]^+$) 390.1676; found 390.1674.

(S)-tert-butyl-3-(hydroxymethyl)-3-(4-methoxybenzyl)-2-oxoindoline-1-carboxylate (3e):⁵




White solid, 37.7 mg, 97% yield, 91% ee; m.p. 99 – 100 °C. $[\alpha]^{30}_D = + 28.0^\circ$ ($c =$

0.93, CHCl_3). Enantiomeric excess was determined by chiral HPLC analysis (CHIRALPAK AS-H, 254

nm, 9:1 hexane/iPrOH, 1.0 mL /min): t_R (major) = 13.67 min, t_R (minor) = 12.41 min. ^1H NMR (300 MHz, CDCl_3): δ = 7.63 (d, J = 8.1 Hz, 1H), 7.28 – 7.19 (m, 1H), 7.17 – 7.05 (m, 2H), 6.77 (d, J = 8.5 Hz, 2H), 6.60 (d, J = 8.4 Hz, 2H), 4.04 – 3.93 (m, 1H), 3.84 (d, J = 11.0 Hz, 1H), 3.67 (s, 3H), 3.08 (q, J = 13.3 Hz, 2H), 2.78 (br s, 1H), 1.55 (s, 9H). ^{13}C NMR (75 MHz, CDCl_3): δ = 178.32, 158.56, 148.92, 140.32, 131.21, 128.75, 128.38, 126.94, 124.42, 123.83, 115.20, 113.45, 84.51, 66.58, 56.58, 55.30, 39.45, 28.24. HRMS (ESI): Calcd. for $\text{C}_{22}\text{H}_{24}\text{FNO}_4\text{Na}$ ($[\text{M}+\text{Na}]^+$) 408.1582; found 408.1581. HRMS (ESI): Calcd. for $\text{C}_{22}\text{H}_{25}\text{NO}_5\text{Na}$ ($[\text{M}+\text{Na}]^+$) 406.1625; found 406.1610.


(*S*)-*tert*-butyl -3-(4-fluorobenzyl)-3-(hydroxymethyl)-5-methyl-2-oxoindoline-1-carboxylate (3f):



White solid, 36.6 mg, 95% yield, 90% ee; m.p. 93 – 94 °C. $[\alpha]_D^{29} = -21.2^\circ$ (c

= 0.97, CHCl_3). Enantiomeric excess was determined by chiral HPLC analysis (CHIRALCEL OD-H, 254 nm, 9:1 hexane/iPrOH, 0.5 mL /min): t_R (major) = 13.78 min, t_R (minor) = 13.34 min. ^1H NMR (300 MHz, CDCl_3): δ = 7.49 (d, J = 8.3 Hz, 1H), 7.04 (d, J = 8.2 Hz, 1H), 6.93 (s, 1H), 6.85 – 6.69 (m, 4H), 4.04 – 3.93 (m, 1H), 3.85 (d, J = 11.0 Hz, 1H), 3.11 (dd, J = 37.9, 13.2 Hz, 2H), 2.65 (d, J = 5.1 Hz, 1H), 2.33 (s, 3H), 1.54 (s, 9H). ^{13}C NMR (75 MHz, CDCl_3): δ = 178.22, 162.02 (d, J = 245.0 Hz), 148.81, 137.92, 134.17, 131.65 (d, J = 8.0 Hz), 130.76 (d, J = 3.3 Hz), 129.43, 127.92, 124.19, 115.06, 114.86 (d, J = 21.2 Hz), 84.48, 66.56, 56.38, 39.43, 28.22, 21.35. ^{19}F NMR (282 MHz, CDCl_3): δ = -116.38 – -116.51 (m). IR (KBr): 3472, 2981, 2922, 2864, 1778, 1701, 1600, 1508, 1482, 1457, 1394, 1371, 1331, 1312, 1283, 1249, 1219, 1156, 1126, 1107, 1071, 950, 888, 834, 763, 718, 661, 615, 605, 564, 502 cm^{-1} . HRMS (ESI): Calcd. for $\text{C}_{22}\text{H}_{24}\text{FNO}_4\text{Na}$ ($[\text{M}+\text{Na}]^+$) 408.1582; found 408.1581.

(*S*)-*tert*-butyl-3-(4-fluorobenzyl)-3-(hydroxymethyl)-5-methoxy-2-oxoindoline-1-carboxylate (3g):




White solid, 36.1 mg, 90% yield, 92% ee; m.p. 118 – 119 °C. $[\alpha]_D^{30} = -$

28.7° (c = 1.09, CHCl_3). Enantiomeric excess was determined by chiral HPLC analysis (CHIRALPAK AS-H, 254 nm, 9:1 hexane/iPrOH, 1.0 mL /min): t_R (major) = 12.90 min, t_R (minor) = 14.93 min. ^1H NMR (300 MHz, CDCl_3): δ = 7.53 (d, J = 8.9 Hz, 1H), 6.88 – 6.80 (m, 2H), 6.79 – 6.70 (m, 3H), 6.67 (d, J = 2.6 Hz, 1H), 4.02 – 3.91 (m, 1H), 3.84 (d, J = 11.0 Hz, 1H), 3.75 (s, 3H), 3.10 (dd, J = 29.2, 13.3 Hz, 2H), 2.77 (d, J = 3.9 Hz, 1H), 1.53 (s, 9H). ^{13}C NMR (75 MHz, CDCl_3): δ = 178.05, 162.03 (d, J = 245.2 Hz), 156.85, 148.82, 133.62, 131.68 (d, J = 8.0 Hz), 130.68 (d, J = 3.3 Hz), 129.43, 116.16, 114.92 (d, J = 21.1 Hz), 113.35, 110.17, 84.47, 66.52, 56.67, 55.82, 39.37, 28.22. ^{19}F NMR (282 MHz,

CDCl₃): δ = -116.26 – -116.40 (m). IR (KBr): 3494, 3045, 2979, 2933, 2837, 1782, 1730, 1600, 1509, 1485, 1456, 1437, 1394, 1370, 1334, 1282, 1247, 1223, 1152, 1074, 1039, 1000, 953, 840, 766, 736, 611, 583, 551 cm⁻¹. HRMS (ESI): Calcd. for C₂₂H₂₄FNO₅Na ([M+Na]⁺) 424.1531; found 424.1528.


(S)-tert-butyl-5-fluoro-3-(hydroxymethyl)-3-(4-methylbenzyl)-2-oxindoline-1-carboxylate (3h):



White solid, 36.2 mg, 94% yield, 89% ee; m.p. 110 – 111 °C. $[\alpha]_D^{30} = +20.2^\circ$

(*c* = 0.99, CHCl₃). Enantiomeric excess was determined by chiral HPLC analysis (CHIRALPAK AD-H, 254 nm, 9:1 hexane/iPrOH, 1.0 mL /min): *t_R* (major) = 6.08 min, *t_R* (minor) = 7.20 min. ¹H NMR (300 MHz, CDCl₃): δ = 7.63 (dd, *J* = 8.9, 4.6 Hz, 1H), 6.99 – 6.81 (m, 4H), 6.77 (d, *J* = 7.9 Hz, 2H), 4.02 (d, *J* = 11.0 Hz, 1H), 3.86 (d, *J* = 11.0 Hz, 1H), 3.09 (q, *J* = 13.2 Hz, 2H), 2.66 (br s, 1H), 2.22 (s, 3H), 1.56 (s, 9H). ¹³C NMR (75 MHz, CDCl₃): δ = 177.79, 159.90 (d, *J* = 243.6 Hz), 148.87, 136.74, 136.24 (d, *J* = 2.3 Hz), 131.38, 130.44 (d, *J* = 8.1 Hz), 130.00, 128.92, 116.48 (d, *J* = 7.9 Hz), 115.18 (d, *J* = 22.8 Hz), 111.44 (d, *J* = 24.4 Hz), 84.67, 66.51, 56.82, 39.91, 28.22, 21.23. ¹⁹F NMR (282 MHz, CDCl₃): δ = -118.13 – -118.26 (m). IR (KBr): 3496, 3131, 3091, 3060, 3013, 2977, 1947, 2913, 2874, 1796, 1711, 1609, 1514, 1479, 1455, 1438, 1396, 1370, 1347, 1306, 1293, 1280, 1246, 1145, 1115, 1099, 1082, 1057, 1028, 1005, 960, 932, 920, 904, 875, 840, 815, 760, 748, 720, 662, 619, 611, 563, 548, 503 cm⁻¹. HRMS (ESI): Calcd. for C₂₂H₂₄FNO₄Na ([M+Na]⁺) 408.1582; found 408.1581.

(S)-tert-butyl-5-fluoro-3-(hydroxymethyl)-3-(4-methoxybenzyl)-2-oxindoline-1-carboxylate (3i):




White solid, 34.1 mg, 85% yield, 91% ee; m.p. 127 – 128 °C. $[\alpha]_D^{30} = +29.1^\circ$

(*c* = 0.81, CHCl₃). Enantiomeric excess was determined by chiral HPLC analysis (CHIRALPAK AD-H, 254 nm, 9:1 hexane/iPrOH, 1.0 mL /min): *t_R* (major) = 8.02 min, *t_R* (minor) = 9.37 min. ¹H NMR (300 MHz, CDCl₃): δ = 7.61 (dd, *J* = 8.9, 4.6 Hz, 1H), 6.98 – 6.83 (m, 2H), 6.79 (d, *J* = 8.6 Hz, 2H), 6.62 (d, *J* = 8.6 Hz, 2H), 4.00 (d, *J* = 11.0 Hz, 1H), 3.85 (d, *J* = 11.0 Hz, 1H), 3.68 (s, 3H), 3.07 (q, *J* = 13.4 Hz, 2H), 2.68 (br s, 1H), 1.55 (s, 9H). ¹³C NMR (75 MHz, CDCl₃): δ = 177.81, 159.91 (d, *J* = 243.5 Hz), 158.69, 148.83, 136.23 (d, *J* = 2.4 Hz), 131.14, 130.48 (d, *J* = 8.1 Hz), 126.52, 116.49 (d, *J* = 7.9 Hz), 115.18 (d, *J* = 22.8 Hz), 113.57, 111.40 (d, *J* = 24.4 Hz), 84.70, 66.46, 56.97, 55.31, 39.48, 28.22. ¹⁹F NMR (282 MHz, CDCl₃): δ = -118.09 – -118.25 (m). IR (KBr): 3489, 3094, 3071, 3007, 2982, 2935, 2876, 2839, 2794, 1792, 1706, 1610, 1510, 1481, 1457, 1439, 1394, 1371, 1350, 1301, 1286, 1246,

1182, 1144, 1116, 1099, 1083, 1029, 960, 934, 905, 876, 850, 836, 811, 764, 748, 721, 661, 612, 565, 527 cm⁻¹. HRMS (ESI): Calcd. for C₂₂H₂₄FNO₅Na ([M+Na]⁺) 424.1531; found 424.1534.


(S)-tert-butyl-3-benzyl-5-fluoro-3-(hydroxymethyl)-2-oxoindoline-1-carboxylate (3j):



White solid, 35.3 mg, 95% yield, 90% ee; m.p. 102 – 103 °C. [α]_D³⁰ = + 26.3°

(*c* = 0.81, CHCl₃). Enantiomeric excess was determined by chiral HPLC analysis (CHIRALPAK AD-H, 254 nm, 9:1 hexane/iPrOH, 0.8 mL /min): *t_R* (major) = 8.98 min, *t_R* (minor) = 8.14 min. ¹H NMR (300 MHz, CDCl₃): δ = 7.61 (dd, *J* = 8.9, 4.6 Hz, 1H), 7.15 – 7.04 (m, 3H), 6.98 – 6.82 (m, 4H), 4.03 (d, *J* = 11.0 Hz, 1H), 3.89 (d, *J* = 11.0 Hz, 1H), 3.14 (dd, *J* = 30.3, 13.2 Hz, 2H), 2.68 (br s, 1H), 1.55 (s, 9H). ¹³C NMR (75 MHz, CDCl₃): δ = 177.67, 159.92 (d, *J* = 243.6 Hz), 148.81, 136.22 (d, *J* = 2.4 Hz), 134.56, 130.31 (d, *J* = 8.1 Hz), 130.10, 128.20, 127.22, 116.47 (d, *J* = 7.9 Hz), 115.24 (d, *J* = 22.8 Hz), 111.43 (d, *J* = 24.4 Hz), 84.71, 66.53, 56.81, 40.34, 28.22. ¹⁹F NMR (282 MHz, CDCl₃): δ = -118.08 – -118.20 (m). IR (KBr): 3504, 3085, 3028, 3008, 2971, 2938, 2876, 1775, 1700, 1605, 1583, 1475, 1457, 1396, 1373, 1308, 1285, 1247, 1152, 1124, 1100, 1077, 1034, 955, 935, 902, 864, 838, 743, 704, 660, 611, 565, 534 cm⁻¹. HRMS (ESI): Calcd. for C₂₁H₂₂FNO₄Na ([M+Na]⁺) 394.1425; found 394.1428.


(S)-tert-butyl-3-(4-fluorobenzyl)-3-(hydroxymethyl)-2-oxoindoline-1-carboxylate (3k):⁵



White solid, 35.2 mg, 95% yield, 91% ee; m.p. 102 – 103 °C. [α]_D²⁹ = + 18.0° (*c* =

0.79, CHCl₃). Enantiomeric excess was determined by chiral HPLC analysis (CHIRALCEL OD-H, 254 nm, 20:1 hexane/iPrOH, 0.5 mL /min): *t_R* (major) = 24.88 min, *t_R* (minor) = 26.93 min. ¹H NMR (300 MHz, CDCl₃): δ = 7.62 (d, *J* = 8.0 Hz, 1H), 7.29 – 7.20 (m, 1H), 7.19 – 7.08 (m, 2H), 6.86 – 6.69 (m, 4H), 3.98 (d, *J* = 6.7 Hz, 1H), 3.86 (d, *J* = 11.0 Hz, 1H), 3.13 (dd, *J* = 35.9, 13.3 Hz, 2H), 2.66 (br s, 1H), 1.56 (s, 9H). ¹³C NMR (75 MHz, CDCl₃): δ = 178.05, 162.03 (d, *J* = 245.1 Hz), 148.78, 140.29, 131.64 (d, *J* = 8.0 Hz), 130.68 (d, *J* = 3.3 Hz), 128.96, 128.00, 124.53, 123.68, 115.27, 114.91 (d, *J* = 21.2 Hz), 84.68, 66.56, 56.40, 39.42, 28.22. ¹⁹F NMR (282 MHz, CDCl₃): δ = -116.26 – -116.47 (m). HRMS (ESI): Calcd. for C₂₁H₂₂FNO₄Na ([M+Na]⁺) 394.1425; found 394.1426.


(S)-tert-butyl-5-fluoro-3-(4-fluorobenzyl)-3-(hydroxymethyl)-2-oxoindoline-1-carboxylate (3l):



White solid, 37.4 mg, 96% yield, 70% ee; m.p. 104 – 105 °C. $[\alpha]_D^{30} = +15.2^\circ$

($c = 1.18$, CHCl_3). Enantiomeric excess was determined by chiral HPLC analysis (CHIRALPAK AD-H, 254 nm, 9:1 hexane/iPrOH, 1.0 mL/min): t_R (major) = 6.43 min, t_R (minor) = 7.12 min. ^1H NMR (300 MHz, CDCl_3): $\delta = 7.59$ (dd, $J = 8.8, 4.8$ Hz, 1H), 7.00 – 6.87 (m, 2H), 6.87 – 6.69 (m, 4H), 4.00 (d, $J = 10.7$ Hz, 1H), 3.88 (d, $J = 11.0$ Hz, 1H), 3.11 (dd, $J = 39.0, 13.3$ Hz, 2H), 2.77 (br s, 1H), 1.54 (s, 9H). ^{13}C NMR (75 MHz, CDCl_3): $\delta = 177.52, 162.09$ (d, $J = 245.5$ Hz), 159.96 (d, $J = 243.9$ Hz), 148.68, 136.19 (d, $J = 2.3$ Hz), 131.55 (d, $J = 8.0$ Hz), 130.32 (d, $J = 3.3$ Hz), 130.18 (d, $J = 8.1$ Hz), 116.56 (d, $J = 7.9$ Hz), 115.35 (d, $J = 24.1$ Hz), 115.05 (d, $J = 21.3$ Hz), 111.30 (d, $J = 24.4$ Hz), 84.87, 66.46, 56.94, 39.47, 28.18. ^{19}F NMR (282 MHz, CDCl_3): $\delta = -115.94 - -116.11$ (m), $-117.84 - -117.99$ (m). IR (KBr): 3490, 3075, 3012, 2941, 2880, 1777, 1702, 1606, 1512, 1486, 1476, 1463, 1456, 1397, 1385, 1369, 1307, 1249, 1224, 1153, 1076, 1048, 953, 936, 903, 864, 840, 765, 719, 659, 611, 567, 547 cm^{-1} . HRMS (ESI): Calcd. for $\text{C}_{21}\text{H}_{21}\text{F}_2\text{NO}_4\text{Na}$ ($[\text{M}+\text{Na}]^+$) 412.1331; found 412.1331.


(S)-tert-butyl-7-fluoro-3-(4-fluorobenzyl)-3-(hydroxymethyl)-2-oxoindoline-1-carboxylate (3m):



White solid, 35.0 mg, 90% yield, 41% ee; m.p. 103 – 104 °C. $[\alpha]_D^{30} = +2.8^\circ$ ($c =$


1.06, CHCl_3). Enantiomeric excess was determined by chiral HPLC analysis (CHIRALPAK AD-H, 254 nm, 9:1 hexane/iPrOH, 1.0 mL/min): t_R (major) = 9.14 min, t_R (minor) = 7.93 min. ^1H NMR (300 MHz, CDCl_3): $\delta = 7.20 - 7.10$ (m, 1H), 7.08 – 6.94 (m, 2H), 6.82 – 6.69 (m, 4H), 4.03 (d, $J = 11.1$ Hz, 1H), 3.90 (d, $J = 11.1$ Hz, 1H), 3.13 (dd, $J = 46.7, 13.2$ Hz, 2H), 2.78 (br s, 1H), 1.45 (s, 9H). ^{13}C NMR (75 MHz, CDCl_3): $\delta = 177.13, 162.10$ (d, $J = 245.2$ Hz), 148.82 (d, $J = 251.5$ Hz), 146.94, 131.71 (d, $J = 1.9$ Hz), 131.45 (d, $J = 8.0$ Hz), 130.31 (d, $J = 3.2$ Hz), 127.28 (d, $J = 9.3$ Hz), 125.68 (d, $J = 7.0$ Hz), 119.51 (d, $J = 3.5$ Hz), 117.17 (d, $J = 20.7$ Hz), 115.05 (d, $J = 21.2$ Hz), 84.97, 66.39, 57.76, 39.65, 27.68. ^{19}F NMR (282 MHz, CDCl_3): $\delta = -116.11 - -116.28$ (m), -119.77 (dd, $J = 11.1, 4.3$ Hz). IR (KBr): 3508, 3042, 2984, 2935, 1785, 1710, 1628, 1601, 1509, 1488, 1473, 1393, 1369, 1357, 1303, 1271, 1250, 1221, 1189, 1161, 1148, 1073, 959, 909, 843, 791, 762, 748, 732, 710, 699, 650, 608, 586, 560 cm^{-1} . HRMS (ESI): Calcd. for $\text{C}_{21}\text{H}_{21}\text{F}_2\text{NO}_4\text{Na}$ ($[\text{M}+\text{Na}]^+$) 412.1331; found 412.1333.

(S)-tert-butyl-7-fluoro-3-(hydroxymethyl)-3-(4-methylbenzyl)-2-oxoindoline-1-carboxylate (3n):




White solid, 34.3 mg, 89% yield, 81% ee; m.p. 112 – 113 °C. $[\alpha]^{30}_D = +13.6^\circ$ ($c = 0.93$, CHCl_3). Enantiomeric excess was determined by chiral HPLC analysis (CHIRALPAK AD-H, 254 nm, 9:1 hexane/iPrOH, 1.0 mL/min): t_R (major) = 9.24 min, t_R (minor) = 7.44 min. ^1H NMR (300 MHz, CDCl_3): $\delta = 7.19 - 7.08$ (m, 1H), 7.05 – 6.93 (m, 2H), 6.88 (d, $J = 7.8$ Hz, 2H), 6.73 (d, $J = 8.0$ Hz, 2H), 4.04 (d, $J = 11.1$ Hz, 1H), 3.89 (d, $J = 11.1$ Hz, 1H), 3.12 (dd, $J = 36.3, 13.2$ Hz, 2H), 2.75 (br s, 1H), 2.21 (s, 3H), 1.46 (s, 9H). ^{13}C NMR (75 MHz, CDCl_3): $\delta = 177.41, 148.84$ (d, $J = 251.3$ Hz), 147.06, 136.56, 132.02 (d, $J = 1.9$ Hz), 131.45, 129.87, 128.93, 127.27 (d, $J = 9.3$ Hz), 125.55 (d, $J = 7.0$ Hz), 119.64 (d, $J = 3.5$ Hz), 117.01 (d, $J = 20.7$ Hz), 84.69, 66.56, 57.74, 40.05, 27.72, 21.25. ^{19}F NMR (282 MHz, CDCl_3): $\delta = -119.74$ (dd, $J = 11.1, 4.3$ Hz). IR (KBr): 3494, 2982, 2935, 2876, 1789, 1714, 1624, 1596, 1515, 1486, 1465, 1395, 1369, 1355, 1305, 1291, 1278, 1250, 1189, 1146, 1072, 1004, 957, 908, 843, 825, 784, 752, 730, 714, 692, 653, 608, 585, 561, 536 cm^{-1} . HRMS (ESI): Calcd. for $\text{C}_{22}\text{H}_{24}\text{FNO}_4\text{Na}$ ($[\text{M}+\text{Na}]^+$) 408.1582; found 408.1581.

(S)-tert-butyl-3-benzyl-7-fluoro-3-(hydroxymethyl)-2-oxoindoline-1-carboxylate (30):



White solid, 33.8 mg, 91% yield, 67% ee; m.p. 99 – 100 °C. $[\alpha]^{30}_D = +10.4^\circ$ ($c = 1.05$, CHCl_3). Enantiomeric excess was determined by chiral HPLC analysis (CHIRALPAK AD-H, 254 nm, 9:1 hexane/iPrOH, 1.0 mL/min): t_R (major) = 10.58 min, t_R (minor) = 8.00 min. ^1H NMR (300 MHz, CDCl_3): $\delta = 7.18 - 7.04$ (m, 4H), 7.04 – 6.94 (m, 2H), 6.91 – 6.81 (m, 2H), 4.05 (d, $J = 11.0$ Hz, 1H), 3.91 (d, $J = 11.1$ Hz, 1H), 3.17 (dd, $J = 41.6, 13.1$ Hz, 2H), 2.61 (br s, 1H), 1.47 (s, 9H). ^{13}C NMR (75 MHz, CDCl_3): $\delta = 177.32, 148.82$ (d, $J = 251.4$ Hz), 147.02, 134.57, 131.79 (d, $J = 2.0$ Hz), 130.01, 128.23, 127.26 (d, $J = 9.3$ Hz), 127.20, 125.56 (d, $J = 6.9$ Hz), 119.59 (d, $J = 3.5$ Hz), 117.11 (d, $J = 20.7$ Hz), 84.85, 66.57, 57.53, 40.39, 27.76. ^{19}F NMR (282 MHz, CDCl_3): $\delta = -119.72$ (dd, $J = 11.4, 4.3$ Hz). IR (KBr): 3513, 3030, 2983, 2932, 2873, 1784, 1751, 1712, 1626, 1600, 1488, 1455, 1370, 1355, 1297, 1264, 1248, 1195, 1145, 1071, 958, 919, 844, 791, 733, 701, 646, 609, 586, 560 cm^{-1} . HRMS (ESI): Calcd. for $\text{C}_{21}\text{H}_{22}\text{FNO}_4\text{Na}$ ($[\text{M}+\text{Na}]^+$) 394.1425; found 394.1427.


(S)-tert-butyl-3-(hydroxymethyl)-3-methyl-2-oxoindoline-1-carboxylate (3p):⁵



White solid, 25.5 mg, 92% yield, 86% ee; m.p. 82 – 83 °C. $[\alpha]_{29}^D = -7.6^\circ$ ($c = 0.85$,

CHCl_3). Enantiomeric excess was determined by chiral HPLC analysis (CHIRALPAK AS-H, 254 nm, 9:1 hexane/iPrOH, 1.0 mL/min): t_R (major) = 6.79 min, t_R (minor) = 6.20 min. ^1H NMR (300 MHz, CDCl_3): $\delta = 7.81$ (d, $J = 8.1$ Hz, 1H), 7.28 (t, $J = 7.6$ Hz, 1H), 7.23 – 7.09 (m, 2H), 3.90 – 3.77 (m, 1H), 3.71 (d, $J = 10.7$ Hz, 1H), 2.73 (br s, 1H), 1.60 (s, 9H), 1.35 (s, 3H). ^{13}C NMR (75 MHz, CDCl_3): $\delta = 178.92$, 149.37, 139.80, 131.03, 128.67, 124.85, 122.95, 115.33, 84.73, 68.24, 50.97, 28.29, 20.07. HRMS (ESI): Calcd. for $\text{C}_{15}\text{H}_{19}\text{NO}_4\text{Na}$ ($[\text{M}+\text{Na}]^+$) 300.1206; found 300.1208.


(S)-tert-butyl-3-(hydroxymethyl)-2-oxo-3-propylindoline-1-carboxylate (3q):⁵



Viscous, 26.6 mg, 87% yield, 74% ee; $[\alpha]_{30}^D = +6.2^\circ$ ($c = 1.00$, CHCl_3).

Enantiomeric excess was determined by chiral HPLC analysis (CHIRALPAK AS-H, 254 nm, 9:1 hexane/iPrOH, 1.0 mL/min): t_R (major) = 6.46 min, t_R (minor) = 5.20 min. ^1H NMR (300 MHz, CDCl_3): $\delta = 7.81$ (d, $J = 8.1$ Hz, 1H), 7.33 – 7.24 (m, 1H), 7.21 – 7.10 (m, 2H), 3.84 (d, $J = 10.6$ Hz, 1H), 3.72 (d, $J = 10.8$ Hz, 1H), 2.50 (br s, 1H), 1.99 – 1.83 (m, 1H), 1.75 – 1.61 (m, 1H), 1.60 (s, 9H), 1.11 – 0.96 (m, 1H), 0.95 – 0.82 (m, 1H), 0.76 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (75 MHz, CDCl_3): $\delta = 178.53$, 149.27, 140.55, 129.43, 128.60, 124.77, 123.03, 115.23, 84.65, 67.98, 55.81, 36.31, 28.30, 17.56, 14.36. HRMS (ESI): Calcd. for $\text{C}_{17}\text{H}_{23}\text{NO}_4\text{Na}$ ($[\text{M}+\text{Na}]^+$) 328.1519; found 328.1521.


(S)-tert-butyl-3-(hydroxymethyl)-3-isobutyl-2-oxoindoline-1-carboxylate (3r):



White solid, 25.9 mg, 81% yield, 65% ee; m.p. 76 – 77 °C. $[\alpha]_{30}^D = -0.4^\circ$ ($c = 0.86$,

CHCl_3). Enantiomeric excess was determined by chiral HPLC analysis (CHIRALPAK AS-H, 254 nm, 9:1 hexane/iPrOH, 1.0 mL/min): t_R (major) = 5.52 min, t_R (minor) = 4.96 min. ^1H NMR (300 MHz, CDCl_3): $\delta = 7.84$ (d, $J = 8.1$ Hz, 1H), 7.36 – 7.27 (m, 1H), 7.24 – 7.14 (m, 2H), 3.79 (d, $J = 7.9$ Hz, 1H), 3.66 (d, $J = 10.6$ Hz, 1H), 2.53 (br s, 1H), 1.95 (dd, $J = 14.0, 8.2$ Hz, 1H), 1.76 (dd, $J = 14.0, 5.3$ Hz, 1H), 1.63 (s, 9H), 1.44 – 1.27 (m, 1H), 0.67 (t, $J = 7.0$ Hz, 6H). ^{13}C NMR (75 MHz, CDCl_3): $\delta = 178.65$, 149.33, 140.43, 129.28, 128.61, 124.65, 123.47, 115.29, 84.61, 69.43, 55.19, 42.06, 28.30, 25.15, 24.30, 23.05. IR (KBr): 3476, 3129, 3051, 2975, 2946, 2921, 2894, 2872, 1782, 1705, 1609, 1477, 1462, 1396, 1372, 1356, 1315, 1293, 1254, 1239, 1151, 1090, 1073, 1050, 944, 844, 756, 677, 601, 558, 502 cm^{-1} . HRMS (ESI): Calcd. for $\text{C}_{18}\text{H}_{25}\text{NO}_4\text{Na}$ ($[\text{M}+\text{Na}]^+$) 342.1676; found 342.1677.

(S)-tert-butyl-3-(hydroxymethyl)-2-oxo-3-phenylindoline-1-carboxylate (3s):⁵




White solid, 32.6 mg, 96% yield, 30% ee; m.p. 108 – 109 °C. $[\alpha]_D^{29} = -21.6^\circ$ ($c =$


1.09, CHCl_3). Enantiomeric excess was determined by chiral HPLC analysis (CHIRALPAK AD-H, 254 nm, 9:1 hexane/iPrOH, 1.0 mL/min): t_R (major) = 6.97 min, t_R (minor) = 8.52 min. ^1H NMR (300 MHz, CDCl_3): $\delta = 7.97$ (d, $J = 8.1$ Hz, 1H), 7.47 – 7.21 (m, 8H), 4.46 (d, $J = 10.9$ Hz, 1H), 4.18 (d, $J = 10.9$ Hz, 1H), 2.07 (br s, 1H), 1.62 (s, 9H). ^{13}C NMR (75 MHz, CDCl_3): $\delta = 176.14, 149.36, 140.76, 136.70, 129.23, 129.08, 128.92, 128.30, 127.57, 125.16, 124.89, 115.71, 84.85, 67.96, 59.31, 28.30$. HRMS (ESI): Calcd. for $\text{C}_{20}\text{H}_{21}\text{NO}_4\text{Na}$ ($[\text{M}+\text{Na}]^+$) 362.1363; found 362.1364.

4. References.


1. (a) Y. Hamashima, T. Suzuki, H. Takano, Y. Shimura and M. Sodeoka, *J. Am. Chem. Soc.* 2005, **127**, 10164; (b) W. G. Rajeswaran, L. A. Cohen, *Tetrahedron* 1998, **54**, 11375; (c) T. Ishimaru, N. Shibata, J. Nagai, S. Nakamura, T. Toru and S. Kanemasa, *J. Am. Chem. Soc.* 2006, **128**, 16488.
2. X. Gao, J. W. Han and L. M. Wang, *Org. Lett.* 2015, **17**, 4596.
3. (a) N. J. Lajkiewicz, S. P. Roche, B. Gerard and J. A. Porco, Jr. *J. Am. Chem. Soc.* 2012, **134**, 13108; (b) A. Cuenca, M. Medio-Simon, G. A. Aguilar, D. Weibel, A. K. Beck and D. Seebach, *Helv. Chim. Acta.* 2000, **83**, 3153; (c) B. Gerard, G. Jones II and J. A. Porco Jr., *J. Am. Chem. Soc.* 2004, **126**, 13620.
4. L. W. Zou, X. Z. Bao, Y. Y. Ma, Y. M. Song, J. P. Qu and B. M. Wang, *Chem. Commun.* 2014, 5760.
5. X. L. Liu, Y. H. Liao, Z. J. Wu, L. F. Cun, X. M. Zhang and W. C. Yuan, *J. Org. Chem.* 2010, **75**, 4872.

5. HPLC Spectra for 3 (a-s).







No.	Peak Name	Retention Time min	Area mAU*min	Height mAU	Relative Area %	Relative Height %	Amount mg/l
n.a.	toluene	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
1		6.562	121.369	577.717	50.03	53.33	n.a.
2		7.337	121.239	505.622	49.97	46.67	n.a.
Total:			242.607	1083.339	100.00	100.00	









No.	Peak Name	Retention Time min	Area mAU*min	Height mAU	Relative Area %	Relative Height %	Amount mg/l
n.a.	toluene	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
1		6.527	318.764	1487.125	97.01	97.16	n.a.
2		7.387	9.810	43.424	2.99	2.84	n.a.
Total:			328.574	1530.549	100.00	100.00	









No.	Peak Name	Retention Time min	Area mAU*min	Height mAU	Relative Area %	Relative Height %	Amount mg/l
n.a.	toluene	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
1		6.608	9.368	47.640	2.39	3.02	n.a.
2		7.280	383.062	1528.352	97.61	96.98	n.a.
Total:			392.430	1575.992	100.00	100.00	














































































Integration Results							
No.	Peak Name	Retention Time min	Area mAU*min	Height mAU	Relative Area %	Relative Height %	Amount mg/l
n.a.	toluene	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
1		4.940	258.661	1539.836	49.90	55.75	n.a.
2		5.515	259.739	1222.120	50.10	44.25	n.a.
Total:			518.400	2761.955	100.00	100.00	







Integration Results							
No.	Peak Name	Retention Time min	Area mAU*min	Height mAU	Relative Area %	Relative Height %	Amount mg/l
n.a.	toluene	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
1		4.963	45.149	278.121	17.15	21.03	n.a.
2		5.520	218.039	1044.662	82.85	78.97	n.a.
Total:			263.188	1322.783	100.00	100.00	














6. NMR Spectra for 3(a-s), 7(a, b), 8(a, b), 9(a, b) and 4(f, i).




































































































































4f

